Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is researching an investigational drug called REGN5668. Participants will receive additional investigational drugs in combination with REGN5668. These additional drugs include cemiplimab or REGN4018 (with or without sarilumab).
The main purposes of this study are to:
This study has 2 parts. The purpose of Part 1 (Escalation) to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.
The study is looking at several other research questions, including:
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Primary purpose
Allocation
Interventional model
Masking
612 participants in 2 patient groups
Loading...
Central trial contact
Clinical Trials Administrator
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal